Updating the paradigm: inflammation as a targetable modulator of medial vascular calcification.
作者信息
Turner Mandy E, Aikawa Elena
机构信息
Division of Cardiovascular Medicine, Department of Medicine, Center for Interdisciplinary Cardiovascular Sciences, Brigham and Women's Hospital, Harvard Medical School, 3 Blackfan St, Boston, MA 02115, USA.
Division of Cardiovascular Medicine, Department of Medicine, Center for Excellence in Vascular Biology, Brigham and Women's Hospital, Harvard Medical School, 77 Louis Pasteur Ave, Boston, MA 02115, USA.
出版信息
Cardiovasc Res. 2023 Oct 24;119(13):2259-2261. doi: 10.1093/cvr/cvad139.
Abstract
摘要
相似文献
1
Updating the paradigm: inflammation as a targetable modulator of medial vascular calcification.更新范式：炎症作为血管中层钙化的可靶向调节因子
Cardiovasc Res. 2023 Oct 24;119(13):2259-2261. doi: 10.1093/cvr/cvad139.
2
[Vascular Calcification - Pathological Mechanism and Clinical Application - . Mechanisms of vascular calcification].[血管钙化——病理机制与临床应用——. 血管钙化的机制]
Clin Calcium. 2015 May;25(5):635-43.
3
[The mechanisms of medial vascular calcification].[血管中膜钙化的机制]
Sheng Li Xue Bao. 2016 Oct 25;68(5):592-610.
4
The pterostilbene-dihydropyrazole derivative Ptd-1 ameliorates vascular calcification by regulating inflammation.紫檀芪二氢吡唑衍生物 Ptd-1 通过调节炎症改善血管钙化。
Int Immunopharmacol. 2023 Dec;125(Pt B):111198. doi: 10.1016/j.intimp.2023.111198. Epub 2023 Nov 11.
5
The Inhibitory Roles of Vitamin K in Progression of Vascular Calcification.维生素 K 在血管钙化进展中的抑制作用。
Nutrients. 2020 Feb 23;12(2):583. doi: 10.3390/nu12020583.
6
Kv1.3 Channel, a Targetable Piece in the Complex Jigsaw Puzzle of Vascular Calcification?Kv1.3通道，血管钙化复杂拼图中一个可靶向的部分？
Function (Oxf). 2020 Dec 28;2(1):zqaa049. doi: 10.1093/function/zqaa049. eCollection 2021.
7
Endothelin type A receptor blockade reduces vascular calcification and inflammation in rats with chronic kidney disease.内皮素A型受体阻断可减轻慢性肾脏病大鼠的血管钙化和炎症。
J Hypertens. 2017 Feb;35(2):376-384. doi: 10.1097/HJH.0000000000001161.
8
Targeting vascular smooth muscle cell dysfunction with xanthine derivative KMUP-3 inhibits abdominal aortic aneurysm in mice.黄嘌呤衍生物 KMUP-3 通过靶向血管平滑肌细胞功能障碍抑制小鼠腹主动脉瘤。
Atherosclerosis. 2020 Mar;297:16-24. doi: 10.1016/j.atherosclerosis.2020.01.029. Epub 2020 Feb 6.
9
Vascular calcification: pathophysiology and clinical implications.血管钙化：病理生理学与临床意义
Einstein (Sao Paulo). 2013 Jul-Sep;11(3):376-82. doi: 10.1590/s1679-45082013000300021.
10
A nonobstructive condition: Medial arterial calcification.一种非阻塞性疾病：股动脉钙化。
Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2023 Apr 28;48(4):608-613. doi: 10.11817/j.issn.1672-7347.2023.220214.
引用本文的文献
1
Vascular inflammation in chronic kidney disease: the role of uremic toxins in macrophage activation.慢性肾脏病中的血管炎症：尿毒症毒素在巨噬细胞激活中的作用。
Front Cardiovasc Med. 2025 Mar 25;12:1574489. doi: 10.3389/fcvm.2025.1574489. eCollection 2025.
2
Connexin43, A Promising Target to Reduce Cardiac Arrhythmia Burden in Pulmonary Arterial Hypertension.缝隙连接蛋白 43：降低肺动脉高压性心律失常负担的有前途靶点
Int J Mol Sci. 2024 Mar 14;25(6):3275. doi: 10.3390/ijms25063275.
本文引用的文献
1
Sodium-glucose cotransporter 2 inhibitor canagliflozin alleviates vascular calcification through suppression of nucleotide-binding domain, leucine-rich-containing family, pyrin domain-containing-3 inflammasome.钠-葡萄糖协同转运蛋白 2 抑制剂卡格列净通过抑制核苷酸结合域、富含亮氨酸重复家族、吡咯烷酮域-3 炎性小体缓解血管钙化。
Cardiovasc Res. 2023 Oct 24;119(13):2368-2381. doi: 10.1093/cvr/cvad119.
2
Cardiovascular Calcification Heterogeneity in Chronic Kidney Disease.慢性肾脏病中心血管钙化的异质性。
Circ Res. 2023 Apr 14;132(8):993-1012. doi: 10.1161/CIRCRESAHA.123.321760. Epub 2023 Apr 13.
3
Targeting inflammation in atherosclerosis - from experimental insights to the clinic.靶向动脉粥样硬化炎症——从实验研究到临床实践。
Nat Rev Drug Discov. 2021 Aug;20(8):589-610. doi: 10.1038/s41573-021-00198-1. Epub 2021 May 11.
4
SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control.钠-葡萄糖协同转运蛋白 2 抑制剂：除血糖控制之外的心血管获益机制。
Nat Rev Cardiol. 2020 Dec;17(12):761-772. doi: 10.1038/s41569-020-0406-8. Epub 2020 Jul 14.
5
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease.卡那奴单抗治疗动脉粥样硬化疾病的抗炎疗法。
N Engl J Med. 2017 Sep 21;377(12):1119-1131. doi: 10.1056/NEJMoa1707914. Epub 2017 Aug 27.
6
A randomised study of the impact of the SGLT2 inhibitor dapagliflozin on microvascular and macrovascular circulation.钠-葡萄糖协同转运蛋白2抑制剂达格列净对微血管和大血管循环影响的随机研究
Cardiovasc Diabetol. 2017 Feb 23;16(1):26. doi: 10.1186/s12933-017-0510-1.
7
Zooming in on the genesis of atherosclerotic plaque microcalcifications.聚焦动脉粥样硬化斑块微钙化的起源。
J Physiol. 2016 Jun 1;594(11):2915-27. doi: 10.1113/JP271339. Epub 2016 May 1.
8
Genesis and growth of extracellular-vesicle-derived microcalcification in atherosclerotic plaques.动脉粥样硬化斑块中细胞外囊泡衍生的微钙化的形成与生长
Nat Mater. 2016 Mar;15(3):335-43. doi: 10.1038/nmat4519. Epub 2016 Jan 11.
9
Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes.恩格列净对2型糖尿病患者血压、动脉僵硬度标志物及血管阻力的影响。
Diabetes Obes Metab. 2015 Dec;17(12):1180-93. doi: 10.1111/dom.12572. Epub 2015 Oct 9.
10
Coronary calcium as a predictor of coronary events in four racial or ethnic groups.冠状动脉钙化作为四个种族或族裔群体中冠状动脉事件的预测指标。
N Engl J Med. 2008 Mar 27;358(13):1336-45. doi: 10.1056/NEJMoa072100.
Zotero 插件